Option chain shows key data for Biodexa Pharmaceuticals's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Biodexa Pharmaceuticals.

Biodexa Pharmaceuticals (NASDAQ:BDRX) Stock, Option Chain

Biodexa Pharmaceuticals

Biodexa Pharmaceuticals PLC is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The company combines approved and developed medications with its proprietary and drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients.

Image

Biotech

General

BDRX

Gaining Momentum, Biodexa Is Advancing Two Recent Acquisitions Through The Clinic

News

Penny Stocks

Health Care

Movers

Biodexa Pharmaceuticals reports updates from the MAGIC-1 study on MTX110 for recurrent glioblastoma. MTX110 has also demonstrated potential in treating diffuse midline glioma, a rare brain cancer, with significant improvements in survival rates in Phase 1 trials.

Why Is Brain Cancer-Focused Biodexa Pharmaceuticals Stock Trading Lower On Thursday?

Untitled design - 2024-10-16T235234.675

Biodexa&#39;s MX-110 Continues To Show Promise In Recurrent Glioblastoma (rGBM), The Deadliest Brain Cancer

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals PLC

BOMBARDIER 6.25% PFD A by Bombardier Inc.

Bombardier Inc

Telsey Advisory Group analyst Dana Telsey maintains G-III Apparel Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIII#NASDAQ">GIII</a>) with a Market Perform and maintains $38 price target.

Price Target

Analyst Ratings

GIII

Telsey Advisory Group Maintains Market Perform on G-III Apparel Group, Maintains $38 Price Target

HSBC

HSBC Announced The Launch Of HSBC Communityworks Opening Doors, A New Program That Offers Home Loan Grants To Homebuyers In Underserved Counties In California, Florida, New York, New Jersey, Virginia, Washington And The District Of Columbia, Effective January 1, 2025

Goldman Sachs analyst Paul Choi initiates coverage on Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) with a Buy rating and announces Price Target of $143.

Initiation

LNTH

Goldman Sachs Initiates Coverage On Lantheus Holdings with Buy Rating, Announces Price Target of $143

Macro Economic Events

Econ #s

Economics

Eurozone Consumer Price Index (YoY) For November 2.2% Vs. 2.3% Est.; 2.0% Prior

Eurozone Consumer Price Index (MoM) For November -0.3% Vs. -0.3% Est.; 0.3% Prior

Eurozone Core Consumer Price Index (YoY) For November 2.7% Vs. 2.7% Est.; 2.7% Prior

Goldman Sachs analyst Paul Choi reinstates Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) with a Neutral and announces $4 price target.

ESPR

Goldman Sachs Reinstates Neutral on Esperion Therapeutics, Announces $4 Price Target

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Biomea Fusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>) with a Buy and maintains $40 price target.

Reiteration

BMEA

HC Wainwright & Co. Reiterates Buy on Biomea Fusion, Maintains $40 Price Target

The U.S. has the world&#8217;s largest companies by market capitalization and about two-thirds of the MSCI World Index is dominated by companies based out of America.
What Happened: U.S.-based companies ranking among the world&#8217;s top ten firms by market capitalization include Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>), Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), and Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>).
These magnificent seven firms along with Broadcom are the beneficiaries of the U.S. tech and AI boom. The remaining two non-U.S. firms that make up the top ten include Saudi Arabian Oil Co and Taiwan Semiconductor Mfg Co Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSMC#NYSE">TSMC</a>).
According to an X post by Kevin Gordon, director and senior investment strategist at Charles Schwab, &#8220;Such an imbalance has not been seen since the late 1980s.&#8221; The data shared by him shows nine out of the top ten companies by market capitalization were based out of the U.S. in the 1980s.
"…the US, with 4% of the world's population, roughly a quarter of global GDP and a third of global profits, now accounts for more than two-thirds of the MSCI World index's capitalization. Such an imbalance has not been seen since the late 1980s…,&#8221; he said.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">"…the US, with 4% of the world's population, roughly a quarter of global GDP and a third of global profits, now accounts for more than two-thirds of the MSCI World index's capitalization. Such an imbalance has not been seen since the late 1980s…" ⁦<a href="https://twitter.com/Gavekal?ref_src=twsrc%5Etfw">@Gavekal</a>⁩ <a href="https://t.co/OKO0XCPld5">pic.twitter.com/OKO0XCPld5</a>
&mdash; Kevin Gordon (@KevRGordon) <a href="https://twitter.com/KevRGordon/status/1868748830851633403?ref_src=twsrc%5Etfw">December 16, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: Additionally, the top ten constituents in the MSCI World index are U.S.-based firms. This index captures 1,397 large and mid-cap companies across 23 developed markets.
According <a href="https://www.msci.com/documents/10199/178e6643-6ae6-47b9-82be-e1fc565ededb">to</a> MSCI&#8217;s latest release, dated Nov. 29, the U.S. has a weightage of 73.92% in the index, followed by Japan with 5.23%, the United Kingdom with 3.44%, Canada with 3.1% and France with 2.5%.
The index has the highest exposure of 25.29% to information technology companies, followed by 16.3% to financial firms.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/24/12/42513306/elon-musks-tesla-nearly-5-times-more-expensive-than-industry-average-stock-surges-over-60-since-election">Elon Musk&#8217;s Tesla Nearly 5 Times More Expensive Than Industry Average: Stock Surges Over 60% Since Election</a></li>
</ul>
Photo courtesy: Shutterstock

Equities

Global

Markets

AAPL

AMZN

AVGO

GOOG

GOOGL

MSCI

MSFT

NVDA

TSLA

TSMC

US Stocks Led By Apple, Nvidia, And Other Tech Giants Dominate Nearly Two-Thirds Of MSCI World Index, Drawing Parallels To 1980s Peak

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Tenaya Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNYA#NASDAQ">TNYA</a>) with a Buy and maintains $18 price target.

TNYA

HC Wainwright & Co. Reiterates Buy on Tenaya Therapeutics, Maintains $18 Price Target

Stifel analyst Drew Crum downgrades Electronic Arts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>) from Buy to Hold and maintains the price target from $167 to $167.

Downgrades

Stifel Downgrades Electronic Arts to Hold, Maintains Price Target to $167

HIMX

Himax and Seeed Studio Collaborate To Redefine IoT With AI-Powered SenseCAP Watcher, Debuting At CES 2025

Stifel analyst Brad Reback upgrades Workiva (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WK#NYSE">WK</a>) from Hold to Buy and raises the price target from $102 to $130.

Upgrades

Stifel Upgrades Workiva to Buy, Raises Price Target to $130

Morgan Stanley analyst Eric Serotta maintains Celsius Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>) with a Equal-Weight and lowers the price target from $46 to $42.

CELH

Morgan Stanley Maintains Equal-Weight on Celsius Holdings, Lowers Price Target to $42

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates BioCardia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCDA#NASDAQ">BCDA</a>) with a Buy and maintains $25 price target.

BCDA

HC Wainwright & Co. Reiterates Buy on BioCardia, Maintains $25 Price Target

Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) rose sharply in today's pre-market trading after the company announced it will report on December 18 interim data from its Phase 1 clinical trial evaluating Soquelitinib in patients with moderate to<a href="https://www.benzinga.com/quote/CRVS"> severe atopic dermatitis</a>.
Corvus Pharmaceuticals shares jumped 22.5% to $9.06 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>ParaZero Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRZO#NASDAQ">PRZO</a>) gained 88.8% to $2.89 in pre-market trading after gaining 5% on Tuesday. ParaZero Technologies regained Nasdaq compliance.</li>
<li>Vast Renewables Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTE#NASDAQ">VSTE</a>) climbed 68.4% to $2.19 in pre-market trading after declining over 6% on Tuesday.</li>
<li>Nukkleus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUKK#NASDAQ">NUKK</a>) gained 55.1% to $18.42 in pre-market trading. Nukkleus shares jumped 755% on Tuesday after the company announced it has acquired a 51% controlling stake in Star 26 Capital.</li>
<li>1847 Holdings LLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EFSH#NASDAQ">EFSH</a>) gained 46% to $0.3278 in pre-market trading.</li>
<li>Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) rose 33% to $0.4417 in pre-market trading after dipping 37% on Tuesday.</li>
<li>Rezolve AI Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLV#NASDAQ">RZLV</a>) gained 30.1% to $4.28 in pre-market trading.</li>
<li>CERo Therapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) gained 27.7% to $0.0780 in pre-market trading after jumping 20% on Tuesday.</li>
<li>Richtech Robotics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RR#NASDAQ">RR</a>) gained 26% to $1.55 in pre-market trading after jumping over 26% on Tuesday.</li>
<li>CommScope Holding Company, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COMM#NASDAQ">COMM</a>) rose 9.1% to $6.12 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>NewGenIvf Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares tumbled 29.9% to $0.30 in pre-market trading after jumping 56% on Tuesday.</li>
<li>Petros Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) declined 24% to $0.38 in pre-market trading after jumping 87% on Tuesday.</li>
<li>KWESST Micro Systems Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KWE#NASDAQ">KWE</a>) shares fell 15.5% to $0.71 in pre-market trading after surging over 15% on Tuesday.</li>
<li>Applied DNA Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) shares fell 14.7% to $0.1962 in pre-market trading after reporting weak quarterly sales.</li>
<li>authID Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUID#NASDAQ">AUID</a>) dipped 13.8% to $5.00 in pre-market trading following a 4% decline in the previous session.</li>
<li>FS Bancorp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSBW#NASDAQ">FSBW</a>) fell 13.4% to $39.01 in pre-market trading.</li>
<li>Portage Biotech Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) fell 12.5% to $7.90 in today's pre-market trading after jumping 182% on Tuesday.</li>
<li>SHL Telemedicine Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLT#NASDAQ">SHLT</a>) fell 10% to $3.15 in pre-market trading following a 20% surge on Tuesday.</li>
<li>Southern States Bancshares, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSBK#NASDAQ">SSBK</a>) fell 9.6% to $32.00 in pre-market trading.</li>
<li>Worthington Steel, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WS#NYSE">WS</a>) shares dipped 8.6% to $36.00 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42531171/top-2-utilities-stocks-that-could-sink-your-portfolio-this-quarter">Top 2 Utilities Stocks That Could Sink Your Portfolio This Quarter</a></li>
</ul>

Earnings

Trading Ideas

APDN

AUID

CERO

COMM

CRVS

EFSH

FSBW

NIVF

NUKK

PRTG

PRZO

PTPI

RZLV

SHLT

SSBK

TNXP

VSTE

Why Corvus Pharmaceuticals Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket

Evercore ISI Group analyst Eric Boyes upgrades Dow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>) from In-Line to Outperform and announces $56 price target.

Evercore ISI Group Upgrades Dow to Outperform, Announces $56 Price Target

Micron Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) stock experienced a notable uptick in pre-market trading on Wednesday, climbing by 1.06%. This surge comes as investors eagerly await the company&#8217;s fiscal 2025 first-quarter earnings report.
What Happened: According to&nbsp;<a href="https://pro.benzinga.com/">Benzinga Pro</a>, Micron has seen a substantial 31.89% increase in year-to-date (YTD) returns. The company has consistently <a href="https://www.benzinga.com/24/12/42541544/micron-q1-earnings-preview-analyst-estimates-why-company-is-well-positioned-heading-into-2025">outperformed analyst revenue projections</a>, surpassing expectations in six consecutive quarters and in seven of the last ten quarters overall. 
Analysts are forecasting&nbsp;first-quarter earnings per share of&nbsp;$1.76, a significant improvement&nbsp;from a loss of 95&nbsp;cents per share in the same quarter last year.
Micron has also exceeded analyst earnings per share estimates in three consecutive quarters and in seven of the last ten quarters overall. The company&#8217;s guidance suggests first-quarter revenue will range between $8.5 billion and $8.9 billion, with earnings per share expected to be between $1.66 and $1.82.
See Also:&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42499950/crypto-analyst-shiba-inu-price-set-for-massive-surge-could-go-up-sixfold?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Crypto Analyst: Shiba Inu Price Set For Massive Surge, Could Go Up Sixfold</a>
Why It Matters: The recent performance of Micron Technology is bolstered by a significant investment announcement. On Dec. 10, the <a href="https://www.benzinga.com/news/24/12/42410722/micron-technology-stock-jumps-in-pre-market-after-securing-6-1b-investment-for-us-chip-manufacturing">White House revealed</a> that Micron had secured an investment exceeding $6.1 billion.
This funding will aid in constructing advanced memory chip facilities in Clay, New York, and Boise, Idaho, with Vice President Kamala Harris highlighting the potential creation of at least 20,000 jobs by the decade&#8217;s end.
Additionally, the Department of Commerce has agreed to preliminary terms for a further $275 million investment to expand Micron&#8217;s facility in Manassas, Virginia. This expansion will support critical technologies essential to the defense, automotive, and national security sectors.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/24/12/42485284/billionaire-warren-buffett-paid-120000-for-a-home-but-took-out-a-mortgage-to-do-it-investing-that-money-instead-made-him-2-billion?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Billionaire Warren Buffett Paid $120,000 For A Home But Took Out A Mortgage To Do It – Investing That Money Instead Made Him $2 Billion</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Shutterstock

Pre-Market Outlook

Tech

Micron Technology Rises Ahead Of Earnings Report

Piper Sandler analyst Brent Bracelin maintains Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) with a Overweight and maintains $405 price target.

Piper Sandler Maintains Overweight on Salesforce, Maintains $405 Price Target

Salesforce Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) plans to hire 2,000 people to sell its artificial intelligence products, doubling its previous hiring target announced last month, as the cloud software giant sees strong demand for <a href="https://www.benzinga.com/24/11/42156373/marc-benioff-warns-were-near-the-upper-limits-of-llms-the-future-of-ai-lies-in-autonomous-agents-not-bots-like-chatgpt">its enterprise AI solutions</a>.
What Happened: CEO Marc Benioff revealed the expanded hiring plans at a company <a href="https://www.youtube.com/watch?v=vwgmBsMSwmo">event</a> in San Francisco on Tuesday, noting overwhelming interest with &#8220;9,000 referrals for the 2,000 positions.&#8221; The hiring push comes as Salesforce prepares to launch Agentforce 2.0, its next-generation AI platform, in February 2025.
The increased focus on AI sales represents a strategic shift for Salesforce, which <a href="https://www.benzinga.com/news/24/02/36972435/salesforce-executive-threatens-to-withhold-stock-grants-bonuses-if-employees-fail-to-meet-training-g">laid off over 7,000 employees</a> two years ago amid economic pressures. The company&#8217;s headcount stood at 72,682 as of Jan 31, down about 1% from two years earlier.
Salesforce&#8217;s AI capabilities are already showing promising results in customer service applications. Benioff highlighted that the company&#8217;s AI-powered help page now handles 32,000 conversations weekly, with only 5,000 requiring human escalation – down from 10,000 previously.
Salesforce&#8217;s Agentforce 2.0 serves as a digital labor platform that transforms core business operations. The AI agents autonomously handle sales lead nurturing, provide real-time coaching, prequalify job candidates, and manage customer support 24/7.
See Also: <a href="https://www.benzinga.com/tech/24/12/42547442/microsof-scoops-up-485000-nvidia-ai-chips-twice-as-many-as-its-closest-rival-meta-report">Microsoft Scoops Up 485,000 Nvidia AI Chips, Twice As Many As Its Closest Rival Meta: Report</a>
Why It Matters: The expanded hiring initiative aligns with Salesforce&#8217;s ambitious vision for enterprise AI. Benioff has positioned autonomous AI agents as the next evolution in enterprise software, setting a target of deploying a billion AI agents within a year through the <a href="https://www.benzinga.com/news/management/24/11/41978942/salesforce-ceo-marc-benioff-bets-big-on-billion-bots">company&#8217;s Agentforce platform</a>.
Major customers including Accenture, The Adecco Group, and Indeed are <a href="https://www.benzinga.com/news/contracts/24/12/42532242/salesforce-supercharges-adecco-vivint-with-ai-details">implementing Salesforce&#8217;s AI solutions</a>. Indeed&#8216;s CIO Anthony Moisant said the company is leveraging Agentforce to achieve goals including reducing time-to-hire by 50%.
The move intensifies competition with Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), which has been rolling out its own Copilot AI tools. 
With Agentforce 2.0&#8217;s launch approaching, Salesforce is positioning itself at the forefront of enterprise AI automation, focusing on practical applications that can demonstrate immediate business value rather than theoretical capabilities.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/12/42546044/alex-karp-jokes-about-cult-label-as-stanley-druckenmiller-praises-his-book-after-palantir-soars-nearly-350-in-2024">Palantir&#8217;s Alex Karp Embraces &#8216;Cult&#8217; Status, Complains About The Missing Perks As Stock Soars 350%</a></li>
</ul>
Image via Flickr
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Salesforce Plans Hiring Spree To Sell AI That Cuts Hiring Time And Boosts Sales Productivity

Biodexa Pharmaceuticals (BDRX) has released an update. Biodexa Pharmaceuticals reports promising interim results in their Phase 1 study of MTX110 f...

Biodexa's MTX110 Shows Promise in Brain Cancer Study

Biodexa reports updated Phase 1 data from glioblastoma study

Biodexa announces successful appeal of Nasdaq delisting

Biodexa Pharmaceuticals (BDRX) has released an update. Biodexa Pharmaceuticals has successfully appealed a Nasdaq delisting decision, securing an e...

Biodexa Pharmaceuticals Secures Nasdaq Compliance Extension

Biodexa Pharmaceuticals (BDRX) has released an update. Biodexa Pharmaceuticals has submitted its Form 6-K to the SEC to meet its reporting requirem...

Biodexa Pharmaceuticals Submits SEC Filing with Auditors' Nod

Biodexa Pharmaceuticals (BDRX) has released an update. Biodexa Pharmaceuticals has scheduled a General Meeting to propose resolutions aimed at redu...

Biodexa Pharmaceuticals Plans Strategic Share Value Adjustment

Biodexa Pharmaceuticals (BDRX) announces that the Company has been formally notified that the Nasdaq Hearings Panel of the Nasdaq Stock Marketdeter...

Biodexa Pharmaceuticals regains Nasdaq compliance

Biodexa Pharmaceuticals (BDRX) has released an update. Biodexa Pharmaceuticals has successfully regained compliance with Nasdaq's $1.00 minimum bid...

Biodexa Pharmaceuticals Secures Nasdaq Listing Compliance

Biodexa Pharmaceuticals (BDRX) announces that at its General Meeting held earlier, both resolutions put to the Company's shareholders were duly pas...

Biodexa Pharmaceuticals announces result of general meeting

Biodexa Pharmaceuticals (BDRX) has released an update. Biodexa Pharmaceuticals has successfully passed resolutions at its General Meeting to reduce...

Biodexa Pharmaceuticals Adjusts Share Value Amid Drug Development Focus

Screenshot 2024-07-10 at 9.15.35 PM

Biodexa Announces Additional Positive Results Of Phase 2 Trial Of eRapa In Treatment Of Precancerous Polyps In The GI Tract – Now 12-Month Data

Screenshot 2024-06-03 at 5.21.04 PM

Promising Phase 2 Results For Biodexa&#39;s eRapa™ Indicates Hope For FAP Patients Who Otherwise Have A 100% Lifetime Risk Of Colorectal Cancer

Screenshot 2024-05-08 at 7.48.00 PM

Biodexa Looks To Prevent Or Delay The Worst Outcomes For Adolescents And Young Adults With Devastating Precancerous Condition

Untitled design - 2024-03-28T172702.605

Biodexa&#39;s MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers

Redington 2_29

PowerShares Dynamic Financial Sector Portfolio

Biodexa Takes Aim At Type 1 Diabetes With Innovative Drug Candidate Tolimidone

Press Releases

BDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the Firm

BDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the Firm

Legal

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRX

Notice of General Meeting

Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company")  Regains Compliance For Continued Listing on Nasdaq

Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic

Cardiol Therapeutics (Nasdaq: CRDL) Advances Orphan Drug Designation for CardiolRx™ at the American Heart Association…more stocks inside…

Comments

Biodexa Pharmaceuticals

Biodexa Pharmaceuticals (BDRX) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga